Article
Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor.
The Journal of biological chemistry - 25 Apr 2008
He Yuxian, Xiao Yonghong, Song Haifeng, Liang Qing, Ju Dan, Chen Xin, Lu Hong, Jing Weiguo, Jiang Shibo, Zhang Linqi
Abstract excerpt
Enfuvirtide (T20) is the first and only HIV-1 fusion inhibitor approved for clinical use, but it can easily induce drug resistance limiting its practical application. A novel anti-HIV peptide, termed sifuvirtide, was designed based on the three-dimensional structure of the HIV-1 gp41 fusogenic core conformation. Here we report its in vitro anti-HIV potency, its mechanism of action, as well as the results from...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.